The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20.

Authors

M O Holmström^{1

2}, M D Hjortsø², S M Ahmad², Ö Met^{2

3}, E Martinenaite², C Riley¹, P Straten², I M Svane^{2

3}, H C Hasselbalch¹, M H Andersen^{2

4}

Affiliations

¹ Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
² Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital Herlev, Herlev, Denmark.
³ Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.
⁴ Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

PMID: 27761006
DOI: 10.1038/leu.2016.290

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow Neoplasms / genetics*
Bone Marrow Neoplasms / immunology
Humans
Janus Kinase 2 / genetics*
Mutation
Myeloproliferative Disorders / genetics
T-Lymphocytes / immunology*

Substances

Janus Kinase 2